| Not Yet Recruiting | Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunothera NCT06217666 | Haoming (Carl) Qiu | Phase 1 |
| Recruiting | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma NCT07126158 | Washington University School of Medicine | Phase 2 |
| Recruiting | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers NCT07478523 | University Hospital, Bordeaux | Phase 2 |
| Recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad NCT07491445 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for NCT07493421 | Unidade Local de Saúde São João | N/A |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally A NCT06026943 | Alpha Tau Medical LTD. | N/A |
| Recruiting | 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarci NCT06896188 | Anwaar Saeed | Phase 1 |
| Recruiting | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT NCT06412510 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticanc NCT07093593 | Centre Georges Francois Leclerc | N/A |
| Not Yet Recruiting | Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas NCT06776146 | University Hospital, Bordeaux | — |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Not Yet Recruiting | Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma NCT06892054 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Recruiting | Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic NCT06698458 | Alpha Tau Medical LTD. | N/A |
| Not Yet Recruiting | 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma NCT06911021 | Centre Hospitalier Universitaire Vaudois | N/A |
| Recruiting | Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC) NCT06988150 | Cedars-Sinai Medical Center | — |
| Not Yet Recruiting | Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP ) NCT06743386 | French Society of Digestive Endoscopy | N/A |
| Recruiting | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863 | Clasp Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC NCT06750861 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Not Yet Recruiting | The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Duct NCT06807112 | Charles University, Czech Republic | — |
| Recruiting | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic C NCT06789679 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172 | Epkin | Phase 1 |
| Active Not Recruiting | The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract NCT06728358 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Namodenoson Treatment of Advanced Pancreatic Cancer NCT06387342 | Can-Fite BioPharma | Phase 2 |
| Recruiting | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors NCT06596915 | Shandong Boan Biotechnology Co., Ltd | Phase 1 |
| Active Not Recruiting | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Assoc NCT06115499 | Alliance for Clinical Trials in Oncology | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study of SGN-MesoC2 in Advanced Solid Tumors NCT06466187 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI NCT06333314 | UNICANCER | Phase 2 |
| Completed | Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis NCT06760234 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenoc NCT05624918 | Ashish Manne | Phase 2 |
| Recruiting | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors NCT06399757 | Apollo Therapeutics Ltd | Phase 1 / Phase 2 |
| Recruiting | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer NCT06250972 | Fudan University | Phase 3 |
| Enrolling By Invitation | GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES NCT06102889 | Karolinska University Hospital | — |
| Recruiting | Multicenter Trial of ESK981 in Patients With Select Solid Tumors NCT05988918 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Enrolling By Invitation | The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma NCT06157671 | Adenocyte, LLC | — |
| Recruiting | Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) NCT06024824 | Cancer Trials Ireland | Phase 1 / Phase 2 |
| Recruiting | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer NCT06149689 | Fudan University | Phase 2 |
| Recruiting | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency NCT06095141 | Fudan University | Phase 2 / Phase 3 |
| Recruiting | Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With NCT06199895 | Liu Huang | Phase 2 |
| Recruiting | Impact of Perioperative Nutritional Status and Management in the Context of Resectable Pancreatic Adenocarcino NCT06893536 | University Hospital, Strasbourg, France | — |
| Recruiting | A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advance NCT05657743 | Alpha Tau Medical LTD. | N/A |
| Recruiting | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Posit NCT05877599 | AstraZeneca | Phase 1 |
| Recruiting | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors NCT05769959 | Hoffmann-La Roche | Phase 1 |
| Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors NCT05933265 | Lantern Pharma Inc. | Phase 1 / Phase 2 |
| Terminated | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study NCT04992507 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Prospective Validation of an EHR-based Pancreatic Cancer Risk Model NCT05973331 | Beth Israel Deaconess Medical Center | — |
| Recruiting | Evaluating Novel Therapies in ctDNA Positive GI Cancers NCT05482516 | Georgetown University | Phase 3 |
| Recruiting | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adeno NCT05083247 | Erasme University Hospital | Phase 2 |
| Recruiting | Pancreatic Cancer Detection Consortium NCT06388967 | City of Hope Medical Center | — |
| Completed | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors NCT05795595 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Terminated | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation NCT05737706 | Mirati Therapeutics Inc. | Phase 1 |
| Recruiting | The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer NCT05752812 | Medical University of Vienna | — |
| Active Not Recruiting | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors NCT05651022 | Indaptus Therapeutics, Inc | Phase 1 / Phase 2 |
| Completed | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer NCT05673811 | Theriva Biologics SL | Phase 2 |
| Terminated | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer NCT05546411 | Kimberly Perez, MD | Phase 2 |
| Terminated | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancrea NCT05494866 | German Cancer Research Center | Phase 1 |
| Active Not Recruiting | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors NCT05585320 | Immuneering Corporation | Phase 1 / Phase 2 |
| Recruiting | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Completed | Patient-derived Organoids Drug Screen in Pancreatic Cancer NCT05351983 | Prof. Dr. med. Dres. h.c. Jan Schmidt, MME | N/A |
| Active Not Recruiting | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion NCT05245500 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastro NCT05365581 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients NCT05247164 | IRCCS San Raffaele | N/A |
| Unknown | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors NCT05181605 | Instituto de investigación e innovación biomédica de Cádiz | Phase 2 / Phase 3 |
| Recruiting | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC NCT04605913 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer NCT05077800 | Colin D. Weekes, M.D., PhD | Phase 2 |
| Unknown | Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma NCT05228808 | Sohag University | — |
| Terminated | 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma NCT05239182 | Anwaar Saeed | Phase 2 |
| Withdrawn | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort NCT05287347 | Beth Israel Deaconess Medical Center | — |
| Suspended | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types NCT05000294 | University of Florida | Phase 1 / Phase 2 |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Terminated | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing NCT05380557 | Invitae Corporation | — |
| Active Not Recruiting | mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma NCT04986930 | Asan Medical Center | Phase 2 |
| Terminated | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma NCT04983407 | Aravive, Inc. | Phase 1 / Phase 2 |
| Recruiting | Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC) NCT04926467 | Baylor Research Institute | Phase 2 |
| Recruiting | Activation of Biobank Registry for Bilio-pancreatic Diseases NCT06552078 | IRCCS San Raffaele | — |
| Recruiting | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Active Not Recruiting | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of NCT04539808 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Active Not Recruiting | The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy f NCT04902352 | University Hospital Birmingham NHS Foundation Trust | N/A |
| Unknown | Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemother NCT04835064 | Fudan University | Phase 3 |
| Withdrawn | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pa NCT05056805 | M.D. Anderson Cancer Center | N/A |
| Unknown | Portal Vein Thrombosis Associated With Unresectable Pancreatic Cancers : a Prospective Multicentric Cohort Stu NCT04814251 | Poitiers University Hospital | — |
| Recruiting | Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery NCT04452461 | Hamilton Health Sciences Corporation | Phase 2 |
| Active Not Recruiting | Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Com NCT04837118 | M.D. Anderson Cancer Center | N/A |
| Completed | INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors NCT04436679 | University Hospital, Lille | — |
| Active Not Recruiting | Pancreatic Cancer Biomarker Study NCT04143152 | Van Andel Research Institute | — |
| Active Not Recruiting | Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Ins NCT04098237 | Andrew Hendifar, MD | Phase 2 |
| Recruiting | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid NCT03740256 | Baylor College of Medicine | Phase 1 |
| Completed | Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment NCT04298242 | Stanford University | N/A |
| Active Not Recruiting | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer NCT04002479 | Alpha Tau Medical LTD. | N/A |
| Completed | Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors NCT04400357 | Ruijin Hospital | N/A |
| Active Not Recruiting | Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer NCT04627246 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Completed | Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer NCT05305001 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | — |
| Active Not Recruiting | Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer NCT03245541 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma NCT04157127 | Diakonos Oncology Corporation | Phase 1 |
| Unknown | Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer NCT05400681 | Sonke Detlefsen | — |
| Unknown | FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX NCT04167007 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | KEBI-Cyto Study - Use of the Biocartis Idylla NCT04236102 | Royal Cornwall Hospitals Trust | N/A |
| Completed | Assessment of What Patients and Healthcare Providers Value NCT04483349 | M.D. Anderson Cancer Center | — |
| Completed | Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors NCT04400383 | CARsgen Therapeutics Co., Ltd. | Phase 1 |
| Active Not Recruiting | PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neop NCT06815172 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suff NCT04257448 | GWT-TUD GmbH | Phase 1 / Phase 2 |
| Recruiting | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies NCT04361708 | University of Chicago | Phase 1 |
| Completed | Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocri NCT04406571 | CHU de Reims | — |
| Withdrawn | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma NCT04270929 | Roger Williams Medical Center | Phase 1 |
| Active Not Recruiting | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine NCT03816358 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer NCT04119362 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Active Not Recruiting | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer NCT04137536 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | EUS-guided Laser Ablation in Pancreatic Adenocarcinoma NCT03784417 | Catholic University of the Sacred Heart | N/A |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Terminated | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers NCT04077372 | Stanford University | N/A |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Withdrawn | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancr NCT04130399 | Indiana University | Phase 2 |
| Withdrawn | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors NCT03865563 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | PDAC Peripheral and Portal Vein Sampling NCT04289961 | The Christie NHS Foundation Trust | N/A |
| Active Not Recruiting | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors NCT03851614 | University Health Network, Toronto | Phase 2 |
| Completed | Peptide-based Immunization for Colon- and and Pancreas-carcinoma NCT03871790 | CENTOGENE GmbH Rostock | — |
| Completed | The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma NCT04765410 | Carol Davila University of Medicine and Pharmacy | — |
| Active Not Recruiting | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases NCT03856658 | Corewell Health West | Phase 2 |
| Completed | RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With NCT03745430 | Hellenic Cooperative Oncology Group | Phase 1 / Phase 2 |
| Unknown | A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and NCT03840460 | Royal Marsden NHS Foundation Trust | — |
| Active Not Recruiting | 9-ING-41 in Patients With Advanced Cancers NCT03678883 | Actuate Therapeutics Inc. | Phase 2 |
| Recruiting | Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma NCT06867172 | Carol Davila University of Medicine and Pharmacy | — |
| Recruiting | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP NCT05268692 | Kochi University | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the NCT03483038 | University of Florida | Phase 2 |
| Terminated | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer NCT03723915 | Northwestern University | Phase 2 |
| Unknown | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic an NCT04773769 | Auxilio Mutuo Cancer Center | N/A |
| Completed | EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRIN NCT03126435 | SynCore Biotechnology Co., Ltd. | Phase 3 |
| Unknown | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer NCT03703063 | Benaroya Research Institute | Phase 1 |
| Completed | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC NCT03665441 | ERYtech Pharma | Phase 3 |
| Unknown | Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer NCT03673423 | Ospedale San Raffaele | — |
| Terminated | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma NCT03376659 | Georgetown University | Phase 1 / Phase 2 |
| Unknown | Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma NCT04303403 | National Cancer Centre, Singapore | Phase 1 |
| Withdrawn | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma NCT03649035 | Istituto Clinico Humanitas | Phase 3 |
| Terminated | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors NCT03592264 | OBI Pharma, Inc | Phase 1 / Phase 2 |
| Completed | Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles NCT03567863 | Société Française d'Endoscopie Digestive | N/A |
| Completed | Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer NCT03307564 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Terminated | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma NCT03451773 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology NCT03703089 | Benaroya Research Institute | Phase 1 |
| Unknown | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neo NCT03468244 | Changhai Hospital | N/A |
| Completed | Locally Advanced or Metastatic Pancreatic Adenocarcinoma NCT03559348 | National Health Research Institutes, Taiwan | Phase 2 |
| Unknown | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer NCT03528785 | Centro Ricerche Cliniche di Verona | Phase 2 |
| Completed | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer NCT03225989 | Lokon Pharma AB | Phase 1 / Phase 2 |
| Unknown | The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer NCT03401827 | Seoul National University Hospital | Phase 4 |
| Unknown | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms NCT03435770 | Singapore General Hospital | N/A |
| Terminated | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging NCT06341725 | Paolo Giorgio Arcidiacono, MD | — |
| Recruiting | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery NCT03384238 | George Poultsides | Phase 1 / Phase 2 |
| Completed | Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions NCT03578445 | Herlev Hospital | N/A |
| Completed | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPL NCT03415854 | HonorHealth Research Institute | Phase 2 |
| Completed | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemoth NCT03404960 | University of Pennsylvania | Phase 1 / Phase 2 |
| Completed | Laser Tissue Welding - Distal Pancreatectomy Sealing Study NCT03147768 | Laser Tissue Welding, Inc. | Phase 1 |
| Completed | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer NCT03373188 | Emory University | Phase 1 |
| Completed | Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma NCT03318497 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma NCT03080974 | University of Louisville | Phase 2 |
| Completed | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Duct NCT03193190 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results NCT05226572 | University of Bologna | — |
| Unknown | Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic NCT03202199 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors NCT03507998 | Curegenix Inc. | Phase 1 |
| Active Not Recruiting | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer NCT03138720 | HonorHealth Research Institute | Phase 2 |
| Completed | Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis NCT03152487 | AdventHealth | N/A |
| Unknown | Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarci NCT03159819 | Changhai Hospital | N/A |
| Completed | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer NCT02806687 | University Hospital, Toulouse | Phase 2 |
| Active Not Recruiting | Predicting Effective Therapy in Pancreatic Cancer NCT03033927 | Memorial Sloan Kettering Cancer Center | — |
| Completed | HER-2 Expression in Pancreatic Duct Adenocarcinoma NCT06055647 | Sohag University | — |
| Completed | Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correl NCT02723331 | Academic Thoracic Oncology Medical Investigators Consortium | Phase 2 |
| Unknown | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patient NCT02839343 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Terminated | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma NCT02743975 | University Medical Center Groningen | Phase 1 / Phase 2 |
| Completed | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy NCT02879318 | Canadian Cancer Trials Group | Phase 2 |
| Unknown | Incidence of POPF in the Resection of the Left Pancreas With RFAT NCT03570502 | Hospital del Mar | — |
| Unknown | EUS BD vs ERCP TP for Pancreatic Cancer NCT03063554 | Weill Medical College of Cornell University | N/A |
| Completed | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic NCT02896907 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Active Not Recruiting | Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Ca NCT03073785 | University of Nebraska | Phase 2 |
| Completed | Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruct NCT03054987 | AdventHealth | N/A |
| Terminated | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery NCT02736578 | Eben Rosenthal | Phase 2 |
| Completed | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors NCT02611024 | PharmaMar | Phase 1 / Phase 2 |
| Completed | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer NCT02749136 | Asan Medical Center | Phase 2 |
| Recruiting | High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer Tha NCT02757859 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Unknown | Project Survival-Prospective Biomarker Discovery NCT02781012 | Pancreatic Cancer Research Team | — |
| Completed | Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma NCT03266757 | Hellenic Society of Medical Oncology | — |
| Withdrawn | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma NCT02850874 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients NCT02427841 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Stromal TARgeting for PAncreatic Cancer (STAR_PAC) NCT03307148 | Barts & The London NHS Trust | Phase 1 |
| Active Not Recruiting | Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, an NCT02336087 | City of Hope Medical Center | Phase 1 |
| Completed | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Fo NCT02562716 | SWOG Cancer Research Network | Phase 2 |
| Completed | Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer NCT02550327 | Baylor Research Institute | EARLY_Phase 1 |
| Completed | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combi NCT02586987 | AstraZeneca | Phase 1 |
| Completed | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma NCT02620423 | Oncolytics Biotech | Phase 1 |
| Terminated | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies NCT02638909 | Criterium, Inc. | Phase 2 |
| Completed | Resilience and Exercise in Advanced Cancer Treatment NCT02680990 | Milton S. Hershey Medical Center | N/A |
| Completed | Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With NCT02394535 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma NCT02592395 | The University of Texas Health Science Center, Houston | Phase 1 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Terminated | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study NCT02345460 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma NCT02514421 | The University of Texas Health Science Center, Houston | Phase 1 |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Completed | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Canc NCT02349867 | Virginia Commonwealth University | Phase 1 |
| Unknown | Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue NCT03140592 | Stony Brook University | — |
| Terminated | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer ( NCT02707328 | The Cooper Health System | Phase 1 |
| Unknown | Circulating Tumor DNA Exposure in Peripheral Blood NCT03517332 | Quantgene Inc. | — |
| Completed | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer NCT02333188 | University of Chicago | Phase 1 |
| Withdrawn | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or NCT02496832 | University Health Network, Toronto | N/A |
| Completed | Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma NCT03105921 | Poitiers University Hospital | N/A |
| Completed | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. NCT02072616 | University Hospital, Rouen | N/A |
| Completed | Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer NCT02174887 | Institut Paoli-Calmettes | Phase 1 |
| Terminated | Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation) NCT02838966 | University of Louisville | N/A |
| Terminated | A Study of MLN0264 in Patients With Pancreatic Cancer NCT02202785 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) NCT02124369 | CCTU- Cancer Theme | Phase 2 |
| Active Not Recruiting | Biological and Clinical Database for Pancreatic Adenocarcinoma NCT02818829 | University Hospital, Toulouse | — |
| Active Not Recruiting | Pancreatic Cancer Early Detection Program NCT02206360 | White Plains Hospital | — |
| Terminated | DCE MRI in Patients With Pancreatic Cancer NCT02070705 | OHSU Knight Cancer Institute | N/A |
| Recruiting | Improving Pancreatic Cancer Care by the Use of Computational Science and Technology NCT06055010 | UMC Utrecht | — |
| Completed | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With NCT02045602 | Theriva Biologics SL | Phase 1 |
| Completed | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients W NCT02045589 | Theriva Biologics SL | Phase 1 |
| Unknown | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabi NCT01971281 | NovoCure Ltd. | Phase 1 / Phase 2 |
| Completed | Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma NCT02775786 | Columbia University | N/A |
| Completed | PAncreatic Adenocarcinoma in Hospital NCT01989624 | Centre Hospitalier Departemental Vendee | — |
| Completed | Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer NCT01959672 | University of Nebraska | Phase 2 |
| Terminated | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Pa NCT01921751 | Radiation Therapy Oncology Group | Phase 2 |
| Completed | 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation NCT01764659 | University of Maryland, Baltimore | — |
| Completed | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer NCT01825603 | University of Nebraska | Phase 1 |
| Completed | EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer NCT01834170 | University of Tehran | Phase 1 |
| Completed | A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocar NCT01839799 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adeno NCT01764477 | Prism Pharma Co., Ltd. | Phase 1 |
| Completed | Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surg NCT01783171 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Spectroscopy From Duodenum NCT01753479 | Olympus Corporation | N/A |
| Unknown | A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer NCT02707315 | The Cooper Health System | EARLY_Phase 1 |
| Unknown | Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy NCT06135649 | Universita di Verona | — |
| Completed | Pancreatic Juice Diagnosis From Duodenum NCT01699698 | Olympus Corporation | N/A |
| Completed | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adeno NCT01660711 | Endeavor Health | Phase 2 |
| Completed | Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma NCT01558869 | The University of Hong Kong | Phase 2 |
| Unknown | Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 NCT02133079 | Cure&Sure Biotech Co., LTD | Phase 1 / Phase 2 |
| Completed | Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer NCT01674556 | Haukeland University Hospital | Phase 1 |
| Terminated | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer NCT01897454 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocar NCT01474564 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") NCT01726582 | Medical College of Wisconsin | Phase 2 |
| Terminated | Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer NCT01419002 | CHIR-Net | Phase 3 |
| Recruiting | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and NCT01365169 | M.D. Anderson Cancer Center | N/A |
| Completed | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Ca NCT01369420 | Angiodynamics, Inc. | Phase 2 |
| Completed | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer NCT01389440 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Phase 2 |
| Completed | Diffusion MRI for Pancreatic Adenocarcinoma NCT02896946 | Hospices Civils de Lyon | N/A |
| Completed | Gene Therapy of Pancreatic Ductal Adenocarcinoma NCT01274455 | University Hospital, Toulouse | Phase 1 |
| Terminated | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma NCT01206296 | Medstar Health Research Institute | Phase 2 |
| Completed | Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in NCT01144455 | ImmunoGenesis | Phase 2 |
| Completed | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen Wi NCT01013649 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Second Line Chemotherapy for Advanced Pancreatic Cancer NCT01543412 | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Phase 2 |
| Completed | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer NCT01016483 | EMD Serono | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma NCT00854477 | Cambridge University Hospitals NHS Foundation Trust | Phase 4 |
| Completed | Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancrea NCT01064622 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma NCT01765036 | Société Française d'Endoscopie Digestive | N/A |
| Completed | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer NCT00769483 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) NCT00638612 | Candel Therapeutics, Inc. | Phase 1 |
| Withdrawn | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma NCT00728000 | University of Cincinnati | Phase 2 |
| Unknown | Micrometastasis in Gastrointestinal Cancer NCT01919151 | Oslo University Hospital | — |
| Completed | Endoscopic Ultrasound Elastography in Pancreatic Masses NCT00909103 | University of Medicine and Pharmacy Craiova | — |
| Completed | Safety Study of Modified Vaccinia Virus to Cancer NCT00574977 | David Bartlett | Phase 1 |
| Suspended | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain NCT00637364 | CMED HIFU Development Corporation | Phase 1 / Phase 2 |
| Completed | The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma NCT00644254 | KU Leuven | — |
| Terminated | Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer NCT00593008 | Massachusetts General Hospital | Phase 1 |
| Terminated | A Phase I/Expansion Study of Dasatinib NCT00598091 | Duke University | Phase 1 |
| Terminated | Allogeneic Hematopoietic Stem Cell Transplantation in Pancreatic Adenocarcinoma NCT02207985 | Karolinska Institutet | Phase 1 / Phase 2 |
| Completed | 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Sur NCT00288093 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma NCT00327327 | AmpliMed Corporation | Phase 1 |
| Completed | Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma NCT00203892 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma NCT00154791 | National Taiwan University Hospital | Phase 1 / Phase 2 |
| Recruiting | Prognostic and Predictive Markers of Treatment Response in Patients With PAC. NCT05776342 | GERCOR - Multidisciplinary Oncology Cooperative Group | — |
| Recruiting | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Dis NCT00830557 | Mayo Clinic | — |
| Withdrawn | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic P NCT02575508 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |